IRIS
VENDITTI, ADRIANO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 76.921
EU - Europa 10.511
AS - Asia 10.157
SA - Sud America 1.488
Continente sconosciuto - Info sul continente non disponibili 1.260
AF - Africa 214
OC - Oceania 53
Totale 100.604
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 76.347
SG - Singapore 4.267
IT - Italia 3.080
CN - Cina 2.054
DE - Germania 1.926
RU - Federazione Russa 1.239
BR - Brasile 1.158
HK - Hong Kong 945
UA - Ucraina 921
VN - Vietnam 775
IE - Irlanda 762
BD - Bangladesh 637
GB - Regno Unito 609
FR - Francia 576
FI - Finlandia 335
CA - Canada 326
KR - Corea 318
JP - Giappone 306
SE - Svezia 259
NL - Olanda 238
IN - India 207
PL - Polonia 114
AR - Argentina 109
ES - Italia 95
ID - Indonesia 93
MX - Messico 87
AT - Austria 83
ZA - Sudafrica 73
TR - Turchia 69
EC - Ecuador 55
IQ - Iraq 53
PH - Filippine 51
EG - Egitto 50
AU - Australia 47
IR - Iran 47
CO - Colombia 44
BE - Belgio 43
PK - Pakistan 42
UZ - Uzbekistan 38
JM - Giamaica 34
SA - Arabia Saudita 33
TH - Thailandia 32
VE - Venezuela 31
MY - Malesia 30
PE - Perù 28
CH - Svizzera 26
CZ - Repubblica Ceca 26
CL - Cile 24
LT - Lituania 22
CR - Costa Rica 20
RO - Romania 20
MA - Marocco 19
HN - Honduras 18
IL - Israele 18
PY - Paraguay 18
AE - Emirati Arabi Uniti 16
TW - Taiwan 16
DO - Repubblica Dominicana 15
NP - Nepal 15
TT - Trinidad e Tobago 15
EU - Europa 14
GR - Grecia 14
TN - Tunisia 14
AL - Albania 13
JO - Giordania 13
BB - Barbados 12
EE - Estonia 12
GT - Guatemala 12
DK - Danimarca 11
HR - Croazia 11
LB - Libano 11
PT - Portogallo 11
BO - Bolivia 10
KE - Kenya 10
KZ - Kazakistan 10
NG - Nigeria 10
BG - Bulgaria 9
DZ - Algeria 9
KG - Kirghizistan 9
UY - Uruguay 9
NI - Nicaragua 8
SN - Senegal 8
SV - El Salvador 8
A2 - ???statistics.table.value.countryCode.A2??? 7
AZ - Azerbaigian 7
HU - Ungheria 7
RS - Serbia 7
SK - Slovacchia (Repubblica Slovacca) 7
BY - Bielorussia 6
MD - Moldavia 6
NO - Norvegia 6
PS - Palestinian Territory 6
AO - Angola 5
BH - Bahrain 5
GE - Georgia 5
NZ - Nuova Zelanda 5
PR - Porto Rico 5
QA - Qatar 5
BJ - Benin 4
CY - Cipro 4
Totale 99.299
Salva come PNG Salva come JPEG
Città #
Woodbridge 19.552
Wilmington 17.827
Houston 14.898
Ashburn 2.470
Singapore 2.427
Fairfield 2.148
Ann Arbor 1.556
San Jose 1.514
Chandler 1.429
Hong Kong 915
Seattle 872
Jacksonville 803
Cambridge 749
Beijing 727
Dublin 697
Rome 678
New York 612
Council Bluffs 560
Dearborn 528
Medford 497
Santa Clara 483
Los Angeles 463
Dallas 423
The Dalles 345
Milan 342
Tokyo 258
Ho Chi Minh City 245
Lawrence 234
Buffalo 229
Zhengzhou 212
Lauterbourg 187
Moscow 166
Hanoi 163
Boardman 131
North Bergen 127
São Paulo 125
Chicago 119
Denver 112
San Diego 107
Munich 104
Brooklyn 102
Helsinki 100
Orem 93
Atlanta 89
London 88
Menlo Park 82
Mülheim 80
Phoenix 78
Redwood City 77
Montreal 76
Toronto 75
Warsaw 75
Nuremberg 73
Shanghai 71
Creede 69
Bologna 68
Engelhard 59
Jakarta 58
Naples 58
Hefei 57
Florence 55
Frankfurt am Main 51
San Francisco 51
Johannesburg 50
Nanjing 50
Guangzhou 47
Lappeenranta 47
Redondo Beach 45
Chennai 44
Columbus 43
Stockholm 43
Turin 42
Norwalk 41
Da Nang 40
Rio de Janeiro 40
Philadelphia 39
Amsterdam 38
Boston 37
University Park 37
Bari 36
Brussels 36
Manchester 35
Paris 34
Charlotte 33
Kunming 32
Verona 32
Falls Church 30
Mumbai 30
Ankara 29
Mountain View 29
Poplar 29
Vienna 29
Brasília 28
Center 28
Seoul 28
Madrid 27
Haiphong 26
Palo Alto 26
Miami 25
Del Norte 24
Totale 79.028
Salva come PNG Salva come JPEG
Nome #
La leucemia mieloide acuta nell’anziano. 1.039
Idiopathic thrombocytopenic purpura: current concepts in pathophysiology and management. 686
Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia 659
Enumeration of CD34+ hematopoietic progenitor cells for clinical transplantation: comparison of three different methods 572
BRCA1, PARP1 and γH2AX in acute myeloid leukemia: Role as biomarkers of response to the PARP inhibitor olaparib. 572
A microgranular variant of acute promyelocytic leukemia with atypical morpho-cytochemical features and an early myeloid immunophenotype 547
CD7 expression in acute myeloid leukemia 543
Enumeration of CD34+ hematopoietic progenitor cells for clinical transplantation: comparison of three different methods 535
AML-M0: A review of laboratory features and proposal of new diagnostic criteria 523
A novel t(11;12)(q23-24;q24) in a case of minimally-differentiated acute myeloid leukemia (AML-M0) 522
Minimally differentiated acute myeloid leukemia (AML-MO): a distinct clinico-biologic entity with poor prognosis 519
An allele-specific RT-PCR assay to detect type A mutation of the nucleophosmin-1 gene in acute myeloid leukemia 516
Analysis of the expression of adhesion molecules on CD34+ progenitors from bone marrow, umbilical cord blood and G-CSF mobilized peripheral blood 515
Possibility of long-term remission in patients with advanced hematologic malignancies after reduced intensity conditioning regimen (RIC) and allogeneic stem cell transplantation 511
A monoclonal antibody against mutated nucleophosmin 1 for the molecular diagnosis of acute myeloid leukemias 509
A phase-II trial of all trans retinoic acid and low-dose cytosine arabinoside for the treatment of high-risk myelodysplastic syndromes 509
Positive selection of CD34+ cells by immunoadsorption: factors affecting the final yield and hematopoietic recovery in patients with hematological malignancies and solid tumors 507
Clinical significance of CD38 expression in chronic lymphocytic leukemia 504
All-trans-retinoic acid plus low-doses of cytarabine for the treatment of poor-risk acute myeloid leukemias 502
P-glycoprotein and terminal transferase expression identify prognostic subsets within cytogenetic risk classes in acute myeloid leukemia 492
Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML) 491
M4 acute myeloid leukemia: the role of eosinophilia and cytogenetics in treatment response and survival. The GIMEMA experience. 490
Alternative novel therapies for the treatment of elderly acute myeloid leukemia patients 489
Leukocyte alkaline-phosphatase score in plasma-cell dyscrasias - correlation with disease severity and circulating levels of granulocyte-colony-stimulating factor 488
Biological profile of 23 cases of minimally differentiated acute myeloid leukemia (AML-MO) and its clinical implications 488
Consensus-based definition of unfitness to intensive and non-intensive chemotherapy in acute myeloid leukemia: a project of SIE, SIES and GITMO group on a new tool for therapy decision making 487
Red blood cell depletion of cord blood using hydroxyethylstarch double sedimentation: analysis of 40 cases 486
Intensive treatment of patients age 60 years and older with de novo acute myeloid leukemia - Analysis of prognostic factors 486
Acute megakaryoblastic leukemia: experience of GIMEMA trials 485
Central Nervous System Involvement in Adult Acute Lymphoblastic Leukemia: Diagnostic Tools, Prophylaxis, and Therapy. 485
Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia. 484
The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia. 483
Soluble factors levels in the initial staging of high-grade non-Hodgkin's lymphomas 483
Comparison between conventional banding analysis and FISH screening with an AML specific set of probes in 260 patients 483
Multiparametric analysis for the enumeration of CD34+ cells from bone marrow and stimulated peripheral blood 483
Minimally differentiated acute myeloid leukemia (AML-MO): Comparison of 25 cases with other French-American-British subtypes 481
Autologous stem-cell transplantation for patients with acute myeloid leukemia aged over 60 yr 480
Real-life use of erythropoiesis-stimulating agents in myelodysplastic syndromes: a "Gruppo Romano Mielodisplasie (GROM)" multicenter study 480
Sequential combination of gemtuzumab ozogamicin and standard chemotherapy in older patients with newly diagnosed acute myeloid leukemia: Results of a randomized phase III trial of the EORTC and GIMEMA consortium (AML-17) 478
Diagnosis of acute myeloid leukemia and system Coulter VCS 478
Prognostic relevance of the expression of Tdt and CD7 in 335 cases of acute myeloid leukemia 478
Novel role of triazenes in haematological malignancies: Pilot study of Temozolomide, Lomeguatrib and IL-2 in the chemo-immunotherapy of acute leukaemia 477
Efficacy and safety of human leucocyte interferon-alpha treatment in patients younger than 60 years of age with polycythaemia vera 477
Clinical implications of cytokine and soluble receptor measurements in patients with newly-diagnosed aggressive non-Hodgkin's lymphoma 476
All-trans retinoic acid (ATRA) administration during pregnancy in relapsed acute promyelocytic leukemia 474
Clinical relevance of P-glycoprotein expression in de novo acute myeloid leukemia 473
Biological features of acute myeloid leukemia in the elderly 472
Blood stem cell processing 471
Identification of emerging FLT3 ITD-positive clones during clinical remission and kinetics of disease relapse in acute myeloid leukaemia with mutated nucleophosmin 471
Clinical relevance of minimal residual disease detection in adult acute myeloid leukemia 471
Lecam1/Icam1 ratio identifies a distinct pattern on normal and myelodysplastic bone marrow CD34+ progenitors cells 470
Randomized trial of two schedules of low-dose gemtuzumab ozogamicin as induction monotherapy for newly diagnosed acute myeloid leukaemia in older patients not considered candidates for intensive chemotherapy. A phase II study of the EORTC and GIMEMA leukaemia groups (AML-19). 469
NK Cell Inflammation in the Clinical Outcome of Colorectal Carcinoma 469
O6-(4-Bromothenyl)guanine (PaTrin-2), a novel inhibitor of O6-alkylguanine DNA alkyl-transferase, increases the inhibitory activity of temozolomide against human acute leukaemia cells in vitro 468
High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial 464
In vitro down-regulation of bcl-2 expression by all-trans retinoic acid in AML blasts 463
P-glycoprotein and BCL-2 levels predict outcome in adult acute lymphoblastic leukaemia 461
AML-M0: a biological and clinical profile 460
Clinical significance of bax/bcl-2 ratio in chronic lymphocytic leukemia 458
Chromosomal aberration of the 11q23 locus in acute leukemia and frequency of MLL gene translocation: results in 378 adult patients 453
Recurrence of a t(8;21)-positive acute myeloid leukemia in the form of a granulocytic sarcoma involving cranial bones: a diagnostic and therapeutic challenge 453
Advances in the treatment of elderly and frail patients with acute myeloid leukemia 452
Azacitidine for the treatment of lower risk myelodysplastic syndromes : A retrospective study of 74 patients enrolled in an Italian named patient program. 451
CD7 Expression in acute myeloid leukemia 451
Biological pattern of AML-M0 versus AML-M1: Response 451
Enhancement of anti-leukemia activity of NK cells in vitro and in vivo by inhibition of leukemia cell-induced NK cell damage 451
New reciprocal translocation t(6;10) (q27;q11) associated with idiopathic myelofibrosis and eosinophilia 450
A haematology consensus agreement on antifungal strategies for neutropenic patients with haematological malignancies and stem cell transplant recipients 447
Minimally differentiated acute myeloid-leukemia (aml-mo): cytochemical, immunophenotypic and cytogenetic analysis of 19 cases 447
All-trans retinoic acid and low dose cytosine arabinoside for the treatment of "poor prognosis" acute myeloid leukemia 447
Contribution of immunophenotypic and genotypic analysis to the diagnosis of acute leukemia 446
Combination antifungal therapy for invasive mould diseases in haematologic patients. An update on clinical data 445
Clinical implication of cytokine and soluble receptor measurements in patients with newly diagnosed aggressive non Hodgkin Lymphomas 445
Clinical heterogeneity of idiopathic CD4+T lymphocytopenia 445
Clinical significance of soluble p53 protein in B-cell chronic lymphocytic leukemia 443
Pre-transplant persistence of minimal residual disease does not contraindicate allogeneic stem cell transplantation for adult patients with acute myeloid leukemia 443
Peripheral polyneuropathy during treatment with alpha-2 interferon 441
Retinoic acid and arsenic trioxide for acute promyelocytic leukemia 441
First report of t(8;21)(q22;q22) in a case of de novo acute monoblastic leukemia 440
Red blood cell depletion and cryopreservation of umbilical cord blood (UCB) 439
Multidimensional flow cytometry for detection of minimal residual disease in acute myeloid leukemia 438
The role of interferon alpha-2a in the treatment of cutaneous T-cell lymphomas 437
Role of human leukocyte interferon-alpha in the treatment of patients with polycythemia vera 437
Analysis of treatment failure in patients with minimally differentiated acute myeloid leukemia (AML-M0) 433
Role of Minimal (Measurable) Residual Disease Assessment in Older Patients with Acute Myeloid Leukemia 433
Minimally differentiated acute myeloid leukemia (AML-MO): A distinct clinico-biologic entity with poor prognosis 432
Recombinant interferon alpha 2a, thymopentin and low doses of cytosine arabinoside for the treatment of myelodysplastic syndromes: a pilot study 432
Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia. 432
Cytogenetic and molecular diagnostic characterization combined to post-consolidation minimal residual disease assessment by flow-cytometry improves risk stratification in adult acute myeloid leukemia 431
Cytoplasmic nucleophosmin is not detected in blastic plasmacytoid dendritic cell neoplasm 431
2021 update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party 431
Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia. 430
Immunophenotypic analysis in 119 patients with acute myeloid leukemia following a previous malignancy: a comparison with the immunophenotype of 231 de novo cases 430
P-glycoprotein expression in de novo acute myeloid leukemia 429
Quantitative analysis of P-glycoprotein, Bcl-2 and transferrin receptor allows the stratification of acute myeloid leukemia patients within different prognostic risk classes 428
Pretransplant minimal residual disease level predicts clinical outcome in patients with acute myeloid leukemia receiving high-dose chemotherapy and autologous stem cell transplantation 426
Temsirolimus, an mTOR inhibitor, in combination with lower-dose clofarabine as salvage therapy for older patients with acute myeloid leukaemia: results of a phase II GIMEMA study (AML-1107) 426
Fluorescence in situ hybridization and conventional cytogenetics for the diagnosis of 11q23(+)/MLL+ translocation in leukaemia 426
GIMEMA AIDA 0493 amended protocol for elderly patients with acute promyelocytic leukaemia. Long-term results and prognostic factors. 425
Thoracic cord compression caused by epidural extramedullary hematopoiesis during erythroid-stimulating agent therapy in two patients with myelodysplastic syndromes 425
Totale 47.885
Salva come PNG Salva come JPEG
Categoria #
all - tutte 254.296
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 254.296
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222.176 0 0 0 102 77 247 145 164 212 234 207 788
2022/20233.937 414 306 291 410 264 754 469 242 450 70 186 81
2023/20242.233 169 81 199 80 256 549 139 142 98 72 106 342
2024/20257.074 283 1.455 786 402 193 427 548 419 742 625 572 622
2025/202613.990 1.231 623 1.637 1.056 1.335 586 1.486 1.603 1.491 1.312 932 698
2026/20275.553 974 718 2.313 1.548 0 0 0 0 0 0 0 0
Totale 100.604